Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
detoxified lipooligosaccharide-tetanus toxoid conjugate
- Development stage
- Unknown
- Lead developer
- National Institute on Deafness and other Communication Disorders
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Detoxified lipooligosaccharide-tetanus toxoid conjugate** is an investigational **nontypeable *Haemophilus influenzae* vaccine** developed by the National Institute on Deafness and Other Communication Disorders. It consists of detoxified lipooligosaccharide derived from nontypeable *Haemophilus influenzae* covalently conjugated to tetanus toxoid as a carrier protein. The conjugate is designed to induce anti-lipooligosaccharide antibodies with complement-mediated bactericidal activity against *H. influenzae*, thereby preventing *H. influenzae*-associated otitis media and respiratory tract infection. A Phase I study in healthy adults evaluated intramuscular administration and reported acceptable safety and increased serum anti-lipooligosaccharide antibody responses; no subsequent human development has been identified.
- Other names
- dLOS-TTlipooligosaccharide-tetanus toxoid conjugateNTHi dLOS-TT conjugate
02
Targets
BCR (Immunoglobulin G B Cell Receptor)T-cell receptor recognizing tetanus toxoid-derived peptide–MHC complexLipooligosaccharide of nontypeable Haemophilus influenzae
Beyond the preview
Go deeper on detoxified lipooligosaccharide-tetanus toxoid conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on detoxified lipooligosaccharide-tetanus toxoid conjugate.